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Over 800,000 people undergo Coronary Artery Bypass Graft (CABG) surgery annually 
for management of their Coronary Artery Disease (CAD) worldwide. Postoperative Atrial 
Fibrillation (PoAF) is a complication with a 30%-40% incidence after CABG surgery. PoAF is 
believed to cause additional complications and also possibly increase the total duration of 
hospital stay in these patients. It is also believed that local and systemic inflammation play a role 
in the development of this complication and the -174 G/C IL-6 gene polymorphism modulates 
the inflammatory response.  A study is underway to evaluate any plausible association between 
the -174 G/C IL-6 genotype and PoAF in CABG patients at the Presbyterian University Hospital, 
Pittsburgh, PA. 
As part of an interim analysis of the study with a proposed enrollment of 380 subjects, 
the -174 G/C –Interleukin 6 genotype variant was determined in 91 CABG patients. Heart rate 
and rhythm were monitored continuously until discharge. Twenty nine subjects (31.84%) 
developed PoAF. Multivariate logistic regression analysis included -174 G/C genotype, age, 
race, sex and other risk factors that are considered to be associated with PoAF.  The analysis of 
the collected data revealed age as a significant predictor of PoAF. Subjects older than 65 years 
had 2.7 times higher odds of developing PoAF as compared to subjects who were 65 years old or 
younger. The -174 G/C gene variant or any other predictors were not significantly associated 
with PoAF in these 91 CABG patients. The length of postoperative hospital stay was not found 
  iv
to be significantly associated with the presence of PoAF. However, this could be attributed to 
aggressive management of PoAF by our clinical care team. 
With 15.3 million prevalence (USA-yr 2004) and the leading cause of mortality, CAD 
and its management are of enormous public health importance. PoAF needs to be explored 
further due to its ill defined etiopathology and the increasingly older patient population that 
undergo CABG surgery for their CAD.  Any further knowledge derived on PoAF would pave 
way for better anticipation and prevention of this complication. 
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1.0  INTRODUCTION 
Coronary artery disease (CAD) is a leading cause of mortality in the USA. As per the 
American Heart Association data for the year 2004, CAD was prevalent in 15.3 million people 
and was the cause of death for ~ 2.4 million. Based on the co morbid factors CAD is treated by 
medical management, percutaneous coronary intervention or surgical revascularization with 
coronary artery bypass grafting (CABG).  
Surgical management of these patients is a complex process due to the high prevalence of 
co-morbidities in this patient population. CABG surgery is indicated in people with triple vessel 
disease and seems to offer a survival benefit for patients with impaired left ventricular function 
(1). More than 800,000 people undergo CABG surgery every year worldwide. Even though it is 
considered an essential part of the CAD management, CABG surgery is associated with 
complications such as bleeding, arrhythmias, embolism, stroke and death.   One of these 
complications- atrial arrhythmia known as Atrial Fibrillation (AF) is focused in this study. 
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1.1 CARDIAC SURGERY AND POSTOPERATIVE ATRIAL FIBRILLATION  
1.1.1 Atrial Fibrillation 
Atrial fibrillation (AF) is defined as asynchronous atrial depolarizations without effective 
atrial contraction. AF is also characterized by the presence of rapid, irregularly timed impulses 
reaching the Atrio-Ventricular (AV) node from the atrium and is associated with irregularly 
timed ventricular response. The atrial rate can be between 350 to 600 beats per minute. Due to 
the low pass filtering properties of atrio-ventricular (AV) node, the ventricular response is much 
slower.   
Atrial fibrillation could be Paroxysmal when the duration of episodes can range from a 
few seconds to hours but usually terminates spontaneously within 48 hours; Persistent when AF 
lasts for days and does not terminate spontaneously, but normal sinus rhythm can be restored by 
electrical cardioversion and/or drugs; Permanent: when patients have a long standing history of 
AF (greater than one year), despite prior attempts of cardioversion (electrical and/or 
pharmacologic). 
Atrial fibrillation is present in approximately 1% of the American population (2, 3) and in 
6% of the population above the age of 65 years (4, 5).  These numbers however do not reflect the 
incidence of AF in post cardiac surgical patients.  
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1.1.2 Postoperative AF (PoAF) 
Various studies have shown that Postoperative AF increases the length of hospital stay; 
markedly increases cost and potentially increases the incidence of post-operative stroke (2, 6, 
and 7). Nationally, postoperative atrial fibrillation (AF) is a common complication of cardiac 
surgery, occurring in 25% to 40% of patients and entails total costs of billions of dollars per year 
to treat (8). At University of Pittsburgh Presbyterian University Hospital, over the past few years, 
our patients experience AF in the postoperative period at an average rate of 30% -40%. The 
incidence of postoperative AF increases with the age of the patient. The average age of the 
patient that undergoes CABG surgery has been on the increase due to the improved longevity of 
the population. Prevention of postoperative AF holds a significant role in patient care in the 
cardiac surgery patient population. This prevention can be achieved by learning more about the 
risk factors that may predispose patients to this complication. In previous literature, several 
demographic risk factors including senility, diabetes, COPD, have been found to be significantly 
associated with postoperative AF.    
Coronary artery bypass grafting is believed to be associated with local inflammation due 
to the surgery and also systemic inflammatory response possibly due to the cardiopulmonary 
bypass (CPB). Several factors are believed to modulate the inflammatory response. Research 
studies are being done to measure inflammatory markers such as the cytokine interleukin 6 (IL-
6) and C - reactive protein in the cardiac surgery patient population. Interleukin 6 is a pro-
inflammatory cytokine and major mediator of acute phase inflammatory response. It is also 
believed that some people are genetically predisposed to have a heightened inflammatory 
response. There have been studies performed to assess the relationship of genetic polymorphisms 
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that could affect the expression IL-6. The association between the -174 G/C polymorphism and 
the high production of IL-6 has enabled some investigators to anticipate and treat the patients 
prophylactically to reduce the IL-6 levels (9). 
 It has been suggested that inflammation might play a role in the post cardiac surgery 
complications and there could be a genetic predisposition to develop postoperative 
complications. There have been studies performed in Europe to ascertain this association and it 
has been found that the -174G/C Interleukin-6 promoter gene polymorphism appears to modulate 
the inflammatory response to surgery and to influence the development of postoperative AF. 
These data suggest an inflammatory component of postoperative atrial arrhythmias and a genetic 
predisposition to this complication (10). This polymorphism has also been associated with the 
development of postoperative renal and pulmonary complications (11). There have been other 
single nucleotide polymorphisms (SNP) that are also associated with high IL-6 production after 
CABG surgery (12). 
1.2 GENOMICS 
Genomics is a newly developing field that appears to have a lot of implications in health 
conditions. Cardiac Surgical procedures are complex and cardiac surgery patients have several 
co morbidities that affect their postoperative course adversely. There were studies focused on the 
association of genetic predisposition to surgical outcomes and this new field of perioperative 
genomics has been gaining significance in the last few years (13).  
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1.2.1 Single Nucleotide Polymorphism (SNP)-174 G/C 
In 1998, a functional polymorphism in the promoter region of the IL-6 gene at position –
174 (–174G>C) was identified (14) An in vitro study using transfected human cell line cells 
reported higher baseline IL-6 levels in cells with the G construct compared with those transfected 
with the C allele. Stimulation with lipopolysaccharides or IL-1 resulted in a significantly 
increased IL-6 transcription rate; this effect, however, was restricted to cells with the G allele. In 
another in vitro study using anti-CD3/CD28–stimulated peripheral blood lymphocytes, IL-6 
concentrations were three times higher among carriers of the G allele (15). Additionally, some 
but not all in vivo studies found higher plasma IL-6 concentrations in subjects with the GG 
genotype than among homozygote for the C allele (16).  
Recently, the –174G>C gene polymorphism has even been suggested as a risk factor for 
coronary heart disease, carotid atherosclerosis and stroke (17-20).   Research studies focused on 
probable association between various disease processes and presence of the different genotypes 
of this polymorphism yielded ambivalent results about the protective effects of genotypes GG 
and CC (21). 
1.3 STUDY DESIGN, STATISTICAL CONSDIERATIONS 
University of Pittsburgh Institutional Review Board approval was obtained prior to study 
start. All the enrolled subjects were consented with an IRB approved consent form. 
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The study is designed as an observational study to investigate the association between the 
genotypes of a single nucleotide polymorphism (of the IL-6 gene at position 174) and the 
occurrence of post operative AF in the post CABG surgery patients. Research related tests 
include genotype analysis for the presence of a -174 GG, CC, GC genotypes of the IL-6 gene. 
The target population for the study is post Coronary Artery Bypass Graft (CABG) Surgery 
patients at Presbyterian University Hospital, Pittsburgh. The proposed total enrollment is 380 
subjects. 
In contrast to a clinical trial where causal effects can be attributed to the intervention due 
to the randomization, for observational studies such associations could be tentative. In addition 
to this, an association in itself does not imply causality. However, observational studies yield 
valuable data in a non-invasive way and can be considered as stepping stones towards 
randomized clinical trials. 
 Based on the previous published literature, it is anticipated that of the three genotypes of 
this polymorphism, the frequency of the GG genotype would be higher in this subjects, due to 
the fact all of these patients were diagnosed with coronary artery disease and the GG genotype 
has been suggested as a risk factor for CAD. However there have been a few studies where the 
GG genotype appears to offer protection against Type II diabetes which renders people more 
prone for coronary artery disease (21). 
1.4 REGULATORY AND COORDINATION 
This research is supported by the University of Pittsburgh Genomics Competitive 
Medical Research Fund (CMRF) in which I (Dr.Raghu) am a part of the study’s research team. A 
substantial amount of effort was rendered by me towards the study design and proposal 
submission for the CMRF. The Institutional Review Board approval process including 
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preparation of protocol, informed consent document and review board communications were 
handled entirely by me. The IRB approved protocol is attached in Appendix A. 
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2.0  METHODS 
2.1 RECRUITMENT PROCEDURE AND SUBJECTS 
Patients who underwent the CABG surgery at the Presbyterian University Hospital were 
approached for participation. Since this study was focused on genomic analysis for the SNP, the 
subjects were consented during either pre or post operative period. A 6 ml blood sample from 
each consented subject was collected for the study.  
2.1.1 Genomic techniques 
As per the standard of the Genomics lab, upon receipt in the Core laboratories all blood 
specimens were assigned a GPCL study number, logged in and then aliquoted. One three ml 
aliquot was immediately used for DNA extraction using the Gentra Systems Puregene DNA 
purification protocol and reagents with no deviation from the Gentra protocol.  The remainder of 
the specimen was frozen at -80 ˚C for future use.  Upon completion of the DNA extraction the 
DNA was reconstituted in either TE (10mM Tris pH 8, 1 mM EDTA) or nuclease free water. 
The rehydrated sample was heated to 65°C for 1 hour and then an aliquot is diluted and the 
absorbance read at λ260 nm and λ280 nm using a UV spectrophotometer in order to assess DNA 
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purity and concentration. The concentrated DNA in TE was designated as stock and stored at 
4°C or in water at -80°C. Working dilutions in water or TE were stored at 4°C. 
The concentrated DNA was diluted in nuclease free water to10 ng/µl. The diluted DNA 
was arrayed into 96 well plates and frozen at -20°C until use .The Single Nucleotide 
Polymorphism (SNP) Analysis were done by the TaqMan® method.  
2.2 DATA ACQUISITION 
2.2.1 Data collection  
The predictor variables of interest were selected based on prior literature review. The data 
on demographics and variables of interest were collected from medical records of the enrolled 
subjects. The genomics SNP analysis to determine the genotype was performed as a research 
related procedure and the results were not added to the clinical medical records of the subjects.  
The data on the outcome of interest-development of AF during the postoperative period was also 
collected form the subjects’ medical records. This was possible because as part of their routine 
care the subjects’ heart rhythm is always monitored in the intensive care unit and 24 hour 
telemetry at the step down unit. Any occurrence of AF that resulted in treatment is counted as an 
incidence of AF.  
  9
2.2.2 Data set 
 Data were collected from 91 subjects who consented for study participation. The data 
collection included demographics such as age, race, gender, medical history on chronic diseases 
including presence of diabetes, hypertension, dyslipidemia, smoking history, chronic obstructive 
pulmonary disease (COPD), previous occurrence of AF, treatment with B blockers prior to the 
surgery, preoperative left ventricular ejection fraction (LVEF), previous myocardial infarction, 
redo sternotomy, usage of cardio –pulmonary bypass (CPB), number of coronary artery bypass 
grafts, PoAF and the genotype of the -174 G/C SNP. Table 1 presents a description of the major 
variables included in this study.  
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Table 1.  Description of the Variables 
Name Predictors 
ID Subject ID 
PoAF Postoperative Atrial Fibrillation (outcome variable) 
Age Age in years at diagnosis time of surgery 
Race Subject Race 
Gend Gender 
Dbts Presence of Diabetes 
Hyprtnsn Presence of Hypertension 
Dyslpdmia Presence of Dyslipidemia 
COPD Presence of Chronic Obstructive Pulmonary Disease 
RemteSmk Past Smoking 
Currntsmk Current Smoking 
PreAF Previous AF episode 
PrevMI Previous Myocardial Infarction 
PreBetaBlkr Treatment with B blockers prior to surgery 
SNP Single Nucleotide Polymorphism at the -174 G/C 
location 
Redo Redo Sternotomy 
CPB CardioPulmonaryBypass 
Grafts Number of grafts used 
Hospital Stay Number of days of Hospital Stay 
Other adverse effects Other adverse events during the hospital stay 
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2.3 STATISTICAL ANALYSIS  
This is an interim analysis performed on the data from 91 subjects. It is anticipated that 
this analysis would provide us with insight on the prevalent genotypes of the polymorphism 
studied and also a profile of the enrolled subject population.  
The analysis plan consisted of evaluating variables of interest, computing descriptive 
statistics, and fitting logistic regression model to assess the association between predictor 
variables and the outcome variable- PoAF. The significance level (α) for all analyses was 0.05 
unless otherwise stated. Analyses were carried out using SPSS® software version 15.0.  A 
secondary analysis included a linear regression analysis between the length of hospital stay and 
PoAF. 
2.3.1 Statistical Models 
Logistic regression was selected to analyze the study data. The outcome variable is 
dichotomous- presence or absence of PoAF. This model estimates odds ratio which is the 
probability of developing PoAF over probability of not developing PoAF. The mathematical 
equation for the logistic regression model is given by 
  
Where θ is the probability of the presence of PoAF, x represents a vector of risk variables and β 
represents the log odds ratio associated with the ith risk variable. 
Linear regression analysis was performed to assess any significant association between 
the duration of hospital stay and PoAF. 
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2.3.2 Evaluation of Variables  
The data consisted of categorical predictor variables exclusively, except for the age and 
LVEF of the subjects. Due to the fact that increased age seem to predispose the surgery patients 
for postoperative complications, a new variable ‘Age Category’ was created and ‘age’ was 
dichotomized into two categories, > 65 years and 65 years and younger. Since it is believed that 
people with better left ventricular function (LVEF > 50%) would have better outcomes after the 
surgery, the LVEF was categorized into two groups, < 50% and >50%. Categorical variables 
were binary except for SNP and ‘Number of grafts’ which had 3 and 6 values respectively.  
  13
3.0  RESULTS 
3.1 DESCRIPTIVE STATISTICS 
Descriptive statistics were computed for all relevant variables. The study subject 
population was predominantly male (69%), Caucasian (95.6%), current non-smokers (87.91%), 
hypertensive (82.42%) and first cardiac surgery (92%). Only about 46% were diabetics. The 
mean age was 65.5 years with a minimum of 41 and a maximum of 86 years.  Patients < 65 yrs 
and > 65 years were about equal (47.25%/ 52.75%) as was the history of previous MI present in 
47.25%. PoAF was observed in 29 of the 91 subjects (31.84%) falling within the expected range 
of incidence (30-40%). There were 16 missing values for variable LVEF. 
Tables 2, 3 and 4 and Figures 1-6 present these descriptive statistics. 
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Table 2. Categorical Outcome/ Predictors 
Predictors Value 
Count – 
percentage 
 
Post Operative AF (Outcome) No 62 (68.13%) 
 Yes 29 (31.87%) 
PreOperative AF 0 86 (94.51%) 
 1 5 (5.49%) 
174 G/C SNP CC 41 (45.05%) 
 GC 39 (42.86%) 
 GG 11 (12.09%) 
Age Category < = 65 years 43 (47.25%) 
  > 65 years 48 (52.75%) 
Male Female 28 (30.77%) 
 Male 63 (69.23%) 
 2 5 (5.49%) 
 3 32 (35.16%) 
Number of grafts 4 36 (39.56%) 
 5 16 (17.58%) 
 6 2 (2.2%) 
Preop Beta Blockers 
No 35 (38.46%) 
56 (61.54%) Yes 
Previous MI 
No 48 (52.75%) 
43 (47.25%) Yes 
Race 
Other 4 (4.4%) 
87 (95.6%) White 
Remote Smoking 
No 41 (45.05%) 
50 (54.95%) Yes 
Repeat Sternotomy 
No 84 (92.31%) 
7 (7.69%) Yes 
Current Smoking 
No 80 (87.91%) 
11 (12.09%) Yes 
Diabetes 
No 49 (53.85%) 
42 (46.15%) Yes 
Hypertension 
No 16 (17.58%) 
75 (82.42%) Yes 
Dyslipidemia 
No 15 (16.48%)  
76 (83.52%) Yes 
COPD 
No 77 (84.62%) 
14 (15.38%) Yes 
CPB 
No 16 (17.58%) 
75(82.42%) Yes 
LVEF 
 
<50% 25 (33.3%) 
 > 50% 50 (66.6%) 
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Table 3.  Continuous Predictors 
Predictor Mean Max Median Min Mode 
 Age 65 86 66 41 65 
Hospital Stay- Number of 
days (Outcome) 8 50 7 3 5 
 
 
Table 4.  Descriptive for Age in PoAF subgroups 
 
                  PoAF N Mean Std Dev Std error 
Age(<65)     No      62 63.60 10.534 1.338 
(>65)           Yes  29 69.55 8.724 1.620 
 
 
 
0% 
0% 
0% 
Pe
rcent 
47.25% 
52.75% 
Percentage of Age Categories
0% 
0% 
> 65 years 
< 65 years 
 
Figure 1. Bar chart of Age categories 
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PoAF No PoAF Yes 
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Figure 2. Bar chart of Age categories subset based on PoAF 
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Percent
75% 
50% 
25% 
 
n=16 
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Hypertension
 
Figure 3. Bar chart of Hypertension 
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Hypertension with PoAF
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0% 
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n=14 n=48
Yes
n=2 n=27
Yes No Yes
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Figure 4. Bar chart of Hypertension subset based on PoAF 
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Figure 5. Bar chart of SNP genotypes 
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Figure 6. Bar chart of SNP frequency- subset based on PoAF 
 
Both age categories are about equal proportions however there seem to be a 
predominance of age group >65 years in the subset that developed PoAF.  The t –test to compare 
mean age between the PoAF group (69.55 yrs) and no PoAF group (63.60 yrs) was not 
significant (p-value of 0.10). 
Table of chi-square statistics between the outcome and predictor variables revealed age 
category as a significant predictor (p-value 0.034). None of the other predictors seem to be 
significantly associated. Predictor variable hypertension had a p-value of 0.067. The chi-square 
values are presented in Table 5. 
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Table 5.  Pearson Chi-Squares for the association between predictors and the outcome 
Variable 
Chi-
square p-value 
Age Category 4.492 0.034 
Hypertension 3.354 0.067 
Repeat Sternotomy 2.231 0.135 
Preoperative AF 1.928 0.165 
174 G/C SNP (2 df) 3.087 0.214 
LVEF 0.784 0.376 
Race 0.634 0.426 
CPB 0.422 0.516 
Male 0.202 0.653 
Remote Smoking 0.178 0.673 
Current Smoking 0.116 0.733 
COPD 0.113 0.737 
Previous MI 0.1 0.751 
Diabetes 0.03 0.862 
Dyslipidemia 0.018 0.894 
Preop Beta Blockers 0.005 0.943 
Number of grafts 0.492 0.974 
SNPGG 2.990 0.084 
 
3.2 REGRESSION ANALYSES 
3.2.1 Logistic regression 
Logistic regression analysis with a full model revealed ‘age category’ as a borderline 
significant predictor (p-value 0.055, OR-3.41, 95% CI for OR (0.97, 11.98)) for PoAF. There 
were 16 missing values for LVEF resulting in removal of these data points from the analysis. 
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The analysis was repeated without LVEFCAT (p-value 0.652) and revealed ‘age category’ as a 
significant predictor (p-value 0.031, OR-3.38, 95% CI for OR (1.12, 10.22)). Backward 
stepwise analysis was also performed to determine the significant predictors. The significance 
level was set to 0.10 for variable removal, which revealed ‘age category’ as a significant 
predictor (p-value 0.037, OR-2.7, 95% CI for OR (1.06, 6.85)) as well.  Model fit were assessed 
by Hosmer and Lemeshow Test.  Table 6 present the variables with p-values under 0.10 derived 
from the analyses. 
 
Table 6. Results from Logistic Regression Analyses 
MODELS Predictors with <0.10 p-value 
 Age   (continuous 
instead of 
categorical) 
Age Category 
(categorical 
instead of 
continuous) 
Hypertension PreOpAF SNPGG 
Full Model a 0.019 
 
0.055 0.062   
Models Without LVEF  
         Full Model 0.014 0.031 0.081 0.069  
                                 Full Model 
SNPGG  instead of SNP b 
0.015 0.031 0.081 0.066  
                               Full Model 
SNP CC instead of SNP c 
0.015 0.036  0.087 0.079 
                                    Full Model 
SNPGC instead of SNP d 
0.011 0.032 0.10   
Single predictor- Age 0.013     
Singlepredictor- 
AgeCategory 
  
0.037 
   
a- SNP  with 2 df, GG, GC and CC ,  b- SNP GG vs nonGG ,       c- SNP CC vs nonCC,   d- SNP GC vs nonGC. 
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Because the study is designed to focus on the association between the genotypes and 
PoAF, additional variables SNPHMZGG, SNPHMZCC and SNPHTZGC were created. 
SNPHMZGG was coded 1 for GG homozygote and 0 for the GC heterozygote and the CC 
homozygote. SNPHMZCC was coded 1 for CC homozygote and 0 for the rest. SNPHTZGC was 
coded 1 for the heterozygote and 0 for the homozygote. Logistic regression with the full model 
was repeated with each new SNP variable substituting variable SNP. 
Age Category still remained as a single significant predictor. None of the SNP categories- 
homozygote or heterozygote was significant predictors. The SNPGG homozygote was the least 
frequent of the polymorphisms in the 91 study subjects and had the following values- pvalue of 
0.079, OR 0.12, 95% CI for OR (0.01, 1.28).  Table 6 presents the variables with p-values under 
0.10 derived from the analyses. 
 
Age Category with PoAF
0.055
0.031
0.037
0.031
0.036
0.032
0.037
0.000 0.010 0.020 0.030 0.040 0.050 0.060
Full model with all predictors
Full model without  LVEF
Backward stepwise model
Full M odel with SNPGG instead of SNPnonGG
Full M odel with SNPCC instead of SNPnonCC
Full M odel with SNPGC Vs SNPnon GC (SNPCC+SNPGG) 
Single predictor-Age category
M
od
el
s
p-values
 
Figure 7.  Bar chart of p-values - Age Category  
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Bar chart of p-values -Age with PoAF
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Figure 8.   Bar chart of p-values -Age with PoAF  
 
Figures 7 and 8 present Bar Charts of p-values for the age variable, obtained from different 
logistic regression models both as a categorical and as a continuous variable. 
3.2.2 Linear Regression 
Linear regression was selected to analyze the association between PoAF, other 
postoperative complications and the total duration of hospital stay. The outcome was the duration 
of stay and the predictors were PoAF and other complications. Analysis with all 91 subjects 
revealed other postoperative complications (p-value 0.025) to be significantly associated with the 
postoperative stay but not PoAF. However, review of the histogram of the duration of hospital 
stay revealed an outlier with a value of 50. The analysis was repeated without the outlier, which 
revealed neither PoAF (p-value 0.278) nor other complications (p-value 0.075) to be significant 
predictors of duration of postoperative hospital stay. 
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4.0  DISCUSSION 
Postoperative AF is a common complication after the Cardiac surgery with an incidence 
of 30-40%. The fiscal and clinical ramifications of this complication are substantial. AF plays a 
major role in neurological complications after surgery and also may compromise the cardiac 
hemodynamics. Discovering the etiological factors of this complication can pave the way 
towards prevention which may lead to further reduction in the postoperative morbidity in this 
patient population. There have been several studies aimed at elucidating the pathophysiology and 
etiology behind PoAF during the recent years. The pre and intra operative factors that are 
thought to predispose the patients to AF after surgery are quite a few. This in itself indicates the 
lack of clear understanding on the mechanism behind PoAF which further need to be explored. 
The current study that is under progress is informative as it would yield critical information on 
genotypes of the Coronary Artery Bypass Graft surgery (CABG) patients at the Presbyterian 
Hospital, UPMC. 
Previous publications cited are ambiguous, with few articles suggesting association of the 
-174GG SNP with higher levels of circulating Interleukin 6 (IL-6) and coronary heart disease 
(CHD) and another few suggesting the association of high IL-6 production and CHD with the C 
allele. All subjects in this study had been diagnosed with coronary artery disease. The genotype 
pattern revealed 45% of CC, 43% of GC and 12% of GG. Although not significant with a p-
value of 0.079, the GG genotype has a negative coefficient (β -2.15) as compared to GC and CC 
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together, points towards a probable inverse association of the GG genotype with PoAF. However 
this needs to be explored further with a larger sample size. 
The limitations of this analysis are small sample size and the unavailability of IL-6 levels 
for the subjects which might also offer insight on the inflammatory process in these patients. 
This study is ongoing and further data collection and the final analysis might reveal additional 
information. 
In concordance with the previous published literature, age emerged as the most 
significant predictor variable associated with PoAF. The following variables might be probable 
predictors that need to be explored further with a larger sample size: presence of hypertension, 
SNPGG and pre-operative AF. The linear regression analysis revealed no significant association 
between the postoperative hospital stay and PoAF. This could be attributed to aggressive 
monitoring and management of PoAF in this hospital. 
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5.0  CONCLUSION 
Age emerged as a significant predictor of PoAF in the 91 subjects that underwent CABG 
surgery during the last yea. If the patient is > 65 years old, the odds of AF after the bypass 
surgery increased by a factor of 2.7 (Odds Ratio 2.7). With one year increase in age, the odds of 
PoAF increases by 1.06 times (OR 1.06). These data do not reveal any significant association 
between PoAF and the length of the hospital stay after the bypass surgery. 
 The SNP -174G/C polymorphism does not seem to be associated with PoAF. However, 
in contrary to the anticipated genotype distribution, the GG genotype is the least frequent of the 
three and it would be prudent to continue the study to further explore the genotype distribution in 
this population.  
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APPENDIX A- IRB PROTOCOL 
GENOMICS AND POSTOPERATIVE ATRIAL FIBRILLATION 
A.1 OBJECTIVE AND SPECIFIC AIMS  
• To ascertain a plausible association between a single nucleotide polymorphism: -
174 G/C of the interleukin 6 gene and postoperative Atrial fibrillation in Coronary 
artery bypass  
• To ascertain a plausible association of the above said polymorphism to other post-
operative adverse events including renal and pulmonary complications during the 
postoperative period.  
A.2 BACKGROUND AND SIGNIFICANCE 
A.2.1 Background  
Atrial Fibrillation: 
Atrial fibrillation (AF) is a condition in which there are highly asynchronous atrial 
depolarizations without effective atrial contraction. AF is also characterized by the presence of 
rapid, irregularly timed impulses reaching the AV node from the atrium and is associated with 
irregularly timed ventricular response. The atrial rate can be between 350 to 600 beats per 
minute. Due to the low pass filtering properties of atrio-ventricular (AV) node, the ventricular 
response is much slower.  
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Atrial fibrillation falls within these 3 categories: 
Paroxysmal:  The duration of episodes can range from a few seconds to hours but usually 
terminates spontaneously within 48 hours.  
Persistent:  Persistent AF lasts for days and does not terminate spontaneously, but normal 
sinus rhythm can be restored by electrical cardioversion and/or drugs.  
Permanent:  Includes those patients with a long standing history of AF (greater than one 
year), despite prior attempts of cardioversion (electrical and/or pharmacologic) or in whom 
cardioversion is not considered indicated. 
 
AF is present in approximately 1% of the American population and in 6% of the 
population above the age of 65 years. While this points to AF as the most common of all of the 
sustained arrhythmias, it says little about its incidence after cardiac surgical procedures. 
 
Postoperative AF: 
 Postoperative AF has been shown to increase the length of hospital stay; markedly 
increase cost and potentially increases the incidence of post-operative stroke.  Nationally, 
postoperative atrial fibrillation (AF) is a common complication of cardiac surgery, occurring in 
25% to 40% of patients and total costs of billions of dollars per year to treat  At University of 
Pittsburgh Presbyterian University Hospital, over the past few years, our patients experience AF 
in the postoperative period at an average rate of 30% -40%. The incidence of postoperative AF 
increases with the age of the patient. The average age of the patient that undergoes CABG 
surgery has been on the increase due to the improved longevity of the population. 
 
Coronary artery bypass grafting is associated with systemic inflammatory response. 
There have been studies performed to assess the relationship of genetic polymorphisms that 
could affect the expression of cytokines such as interleukin 6 (IL-6). Interleukin 6 is a pro-
inflammatory cytokine and major mediator of acute phase response. The correlation between the 
-174 G/C polymorphism and the high production of IL-6 has enabled some investigators to 
anticipate and treat the patients prophylactically to reduce the IL-6 levels.  
 
 It has been suggested that inflammation can have a role in the development of atrial 
arrhythmias after cardiac surgery and that genetic predisposition to develop postoperative 
complications exists. There have been studies performed in Europe to ascertain this association 
and it has been found that the -174G/C Interleukin-6 promoter gene variant appears to modulate 
the inflammatory response to surgery and to influence the development of postoperative AF. 
These data suggest an inflammatory component of postoperative atrial arrhythmias and a genetic 
predisposition to this complication, this polymorphism has also been correlated with the 
development of postoperative renal and pulmonary complications.  
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There have been other single nucleotide polymorphisms (SNP) that are associated with 
high IL-6 production after CABG surgery which could also play a role in the development of 
atrial fibrillation and other complications. 
A.2.2 Significance  
 The focus of this pilot study is to find out if a similar association between the -174 
G/C polymorphism and postoperative atrial fibrillation exists in our CABG patient population. 
The data collected can either provide further support to the above study results or provide 
contradicting information. If supportive, this study can assist us in providing an insight on a 
genetic marker that could help us anticipate complications and could enable us to treat them 
prophylactically. 
 The study would also provide us with a biological sample bank to work on when 
additional funding is available to do further analyses on other polymorphisms that could 
potentially influence the expression of inflammatory markers on postoperative complications. 
A.3 RESEARCH DESIGN AND METHODS 
A.3.1 Drug/Device Information: There are no drugs / devices involved in this study. 
A.3.2 Research Design and Methods: 
This pilot study focuses on ascertaining the frequency of -174G/C SNP and to find out 
the association of this SNP with the postoperative complications of the patient, specifically on 
postoperative Atrial Fibrillation. When further information on other polymorphisms is available, 
the biological sample could be a source for further association analyses. 
 
Patients of the investigators that are scheduled for an elective CABG surgery at the 
Presbyterian University hospital will be approached for participation. A total of 380 patients, 
male and female, of age > 18 years that undergo routine isolated CABG surgery will be 
consented and enrolled. Enrolled patients will have a single blood sample of 6 ml drawn when 
routine standard care blood samples are drawn –thus eliminating the need for additional needle 
prick.   
Any personal identifiers on the blood sample tube will be removed and code numbers 
specific for this research study will be affixed on to the samples by the research coordinator 
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before the samples are sent to the Genomics laboratory for analyses. The samples would be 
stored and transported at 4°C to be received by the lab within 4 days of the blood draw. 
 
The samples will be processed and the DNA extracted as per the techniques mentioned 
below. The DNA will be analyzed to ascertain a single nucleotide polymorphism (SNP) at the -
174 G/C location. The remaining extracted DNA will be stored with the code numbers at the 
Genomics laboratory for potential analyses of other polymorphisms at a later time. The samples 
will be under the control of the investigators.  If the subject expresses agreement on the consent 
form to provide their identifiable (SSN, name, dates of service) information along with their 
stored genetic sample, the samples would be provided to other investigators with an approved 
IRB protocol for their genetic research or other research studies This part of the study is optional 
and the subject may choose not to provide their saved samples to other investigators. 
 
The study participants’ medical records will be reviewed for collection of data on 
demographics, past medical history, postoperative course and any adverse events during their 
postoperative hospital stay. Prospective data will be collected until the patient is discharged after 
the CABG surgery.  However, based on the statistical recommendations for the purpose of 
comparability, the data will be analyzed at specific time points -3rd postoperative day, 7th 
postoperative day. 
 
The data collected will be stored with research codes and not with the identifiable 
personal information. The linkage codes will be maintained in a password protected file by the 
research coordinator. 
 
Source of the tissue: 
Patients that undergo isolated CABG surgery will have a single sample of 6 ml drawn 
either prior to their CABG surgery or prior to their discharge after the CABG surgery. The 
samples will have the personal identifiers removed and marked with the research study code 
numbers. The samples will be forwarded to the Genomics laboratory for DNA extraction and 
genotype analyses.  
 
Genomics techniques: 
DNA extraction from whole blood: 
Blood for DNA extraction should be drawn into blood collection tubes containing EDTA 
(Purple top). As per the standard of the Genomics lab, upon receipt in the Core laboratories all 
blood specimens are assigned a GPCL study number, logged in and then aliquoted. One three ml 
aliquot is immediately used for DNA extraction using the Gentra Systems Puregene DNA 
purification protocol and reagents with no deviation from the Gentra protocol.  The remainder of 
the specimen is frozen at -80 ˚C for future use.  Upon completion of the DNA extraction the 
DNA is reconstituted in either TE (10mM Tris pH 8, 1 mM EDTA) or nuclease free water. The 
rehydrated sample is heated to 65°C for 1 hour and then an aliquot in diluted and the absorbance 
read at λ260 nm and λ280 nm using a UV spectrophotometer in order to assess DNA purity and 
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concentration. The concentrated DNA in TE is designated as stock and stored at 4°C or in water 
at -80°C. Working dilutions in water or TE are stored at 4°C. 
 
The concentrated DNA will be diluted in nuclease free water to 10 ng/µl. The diluted 
DNA will be arrayed into 96 well plates and frozen at -20°C until use .The Single Nucleotide 
Polymorphism (SNP) Analysis will be done by the TaqMan® method.  
A.3.3 Data Collection and Statistical Considerations 
The recommendation of the consulting group at the Department of Biostatistics, 
University of Pittsburgh is to use logistic regression analysis.  Univariate models will be 
computed for each of the independent variables to determine significance (and also used for 
subgroup analysis), with complication status as the outcome.  A multivariate model adjusting 
for covariates can then be determined and used to find the adjusted overall odds ratio.   
A.4 HUMAN SUBJECTS 
A.4.1 General Characteristics - Minority Inclusion and Non-Discriminatory Statements 
The racial, gender and ethnic characteristics of the proposed subject population reflects 
the demographics of Pittsburgh and the surrounding area and/or the patient population of the 
University of Pittsburgh Medical Center.  We shall attempt to recruit subjects in respective 
proportion to these demographics. No exclusion criteria shall be based on race, ethnicity, 
gender, or HIV status. 
A.4.2 Inclusion/Exclusion Criteria - Pregnancy and Birth Control Statements 
Inclusion Criteria: 
• Patients that are about to have a Coronary Artery Bypass Grafting Surgery done. 
 
Exclusion Criteria 
• Inability or unwilling to provide an informed consent to the study. 
• Pregnancy and Birth Control Statements: 
• This study does not have any impact on pregnancy or birth control. 
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 A.4.3 Recruitment Procedures 
Patients of the investigators that undergo Coronary Artery Bypass Grafting Surgery will 
be approached for participation. A total of 380 subjects both male and female of age > 18 years 
will be enrolled in the study. 
A.4.4 Risk/Benefit Ratio 
Risks: 
There are no risks associated with the study as the study requires a one time blood sample 
of 6ml (1 teaspoonful) from the participant. This sample will be taken along with the routine 
samples and so does not require a separate venipuncture. 
 
There is a possibility that if the results of the research studies involving your genetic 
material were to become generally known this information could impact future insurability, 
employability, or reproduction plans, or have a negative impact on family relationships. 
 
Benefits: 
 The information derived from the data collected on the genomics and postoperative atrial 
fibrillation might benefit future surgery patients. 
 
DATA SAFETY MONITORING BOARD:  
 
The investigators will serve as a monitoring group for this study. Issues reviewed include 
recruitment, data analysis, and confidentiality to ensure there have been no breeches in subject 
confidentiality and that subject information is only shared with investigators working with the 
protocol.  Scientific literature or abstracts that may have an impact on the safety of study 
participants or the ethics of the research study will be reviewed.  
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A.5 COSTS AND PAYMENTS 
A.5.1 Research Study Costs: 
The subject and/or the insurer will not be billed for the research-only procedures, which 
include the single blood sample genomics analysis and data collection from medical records.  
The study will pay for the research-only services. 
The subject/ third party payer will be billed for routine care services such as their CABG 
surgery, including any applicable co-pays, coinsurance and deductibles. 
A.5.2 Research Study Payments 
There will not be any payments to the subjects for participation in the study. 
A.6 QUALIFICATIONS OF INVESTIGATORS 
 
Lawrence Wei, M.D. is a Clinical Associate Professor of Surgery, and will be the 
principal investigator on this study. He has had over 14 years of experience with Cardiac 
Surgeries and is interested in research activities to reduce complications of Cardiac surgeries. 
 
Ronald Pellegrini, M.D. is a Clinical Professor of Surgery with over 30 years of 
experience .He routinely performs CABGs, valve surgeries and other cardiac surgeries. He will 
be a co investigator on this study. 
 
Daniel Pellegrini, M.D. is a Clinical Assistant Professor at the Division of Cardiothoracic 
Surgery at UPMC. He will be a co investigator in this study. 
 
Kenton Zehr, MD is the Chief of Cardiac Surgery at UPMC. He has extensive experience 
in cardiac surgery and his interests focus on valve and aneurysm surgeries. 
 
Amit Patel, MD is an Assistant Professor of Surgery with the Division of Cardiac 
Surgery at UPMC. He is also the Director of Cardiac Cell Therapy. He will be a co-investigator 
in this study. 
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Giovanni Speziali, MD is an Assistant Professor of Surgery with the Division of Cardiac 
Surgery at UPMC. He was a fellow at Mayo Clinic and joined the division recently. He will be a 
co-investigator in this study. 
 
Christian Bermudez MD is an Assistant Professor of Surgery with the Division of 
Cardiac Surgery at UPMC. He will be a co-investigator in this study. 
 
Yoshiya Toyoda MD PhD. is an Assistant Professor of Surgery with the Division of 
Cardiac Surgery at UPMC. He has extensive experience in cardiothoracic surgical procedures. 
He will be a co-investigator in this study. 
 
Thomas Gleason MD Director of the Center for Thoracic Aortic Disease, Co-Director of 
the Center for Heart Valve Disease, Associate Professor of Surgery, Division of Cardiac Surgery, 
He will be a co-investigator in this study. 
 
 Michael Siegenthaler MD is Associate Director of the Artificial Heart Program, Director 
of Thoracic Endovascular Therapy, Associate Professor of Surgery, Division of Cardiac Surgery. 
He has extensive experience in cardiothoracic procedures. 
 
 Jennifer Gabany CRNP CCRC is a research nurse practitioner with the Division of 
Cardiac Surgery. She will be a co-investigator in this study.  
 
Sujatha Raghu MBBS is a research coordinator with the Division of Cardiothoracic 
Surgery and she will serve as the coordinator and help with the analyses for the study. 
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